{"filings":[{"id":1620436,"accession_number":"0001193125-26-302648","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2026-07-14T13:10:21+00:00","items":["1.02","2.01","1.01","3.01","3.03","5.01","5.02","5.07","8.01","9.01"],"status":"ready","headline":"Ligand completes acquisition of XOMA Royalty for $39.00/share plus CVRs","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Stockholders received $39.00 cash per share plus one CVR per share entitling holder to 75% of net proceeds from certain pending litigation.","Merger approved by stockholders with 15.9M votes for, 98K against; closing occurred July 14, 2026.","XOMA Royalty common stock delisted from Nasdaq; loan agreement with Blue Owl Capital terminated.","New directors appointed: Todd C. Davis, Octavio Espinoza, Andrew Reardon; prior directors resigned.","Leerink Partners and H.C. Wainwright served as financial advisors; Gibson Dunn as legal advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-07-14","daily_digest_url":"/daily/2026-07-14","daily_digest_rank":3},{"id":1029876,"accession_number":"0001193125-26-269734","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2026-06-12T21:22:32+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"XOMA redeems all preferred stock, sets CVR record date; merger closing on July 14","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Redemption of all 984K Series A and 1.76M Series B depositary shares on July 14 at $25/sh plus accrued dividends.","Quarterly preferred dividends: Series A $0.53906/sh, Series B $0.52344/dep; record July 2, pay July 15.","Merger with Ligand expected to close on/about July 14, 2026, subject to remaining conditions.","CVR record date July 13, 2026 at 5pm ET; each common share receives one CVR for contingent Janssen payments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":590679,"accession_number":"0001193125-26-235401","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2026-05-22T10:01:26+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"XOMA Royalty stockholders approve equity plan amendments, new ESPP, and bylaw forum provision","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2010 Long Term Incentive Plan, increasing share reserve by 425,000 and extending term to 2036.","Stockholders approved 2026 Employee Stock Purchase Plan, authorizing 500,000 shares for issuance.","Board adopted bylaw amendments including exclusive forum provision for state and federal securities claims in Nevada.","All seven director nominees elected; Deloitte & Touche ratified as auditor; advisory say-on-pay approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":483556,"accession_number":"0001193125-26-228031","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2026-05-18T13:11:42+00:00","items":["1.01","9.01"],"status":"ready","headline":"XOMA Royalty amends merger agreement to add newly formed holding company for Ligand acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["HoldCo (XOMA Royalty Holdings Corporation) formed on May 15, 2026 and added as party to the Merger Agreement with Ligand Pharmaceuticals.","Amendment No. 1, dated May 16, 2026, among XOMA Royalty, HoldCo, Ligand, and Merger Sub, facilitates the holding company reorganization.","HoldCo will survive the merger as a wholly owned subsidiary of Ligand; references in the Merger Agreement are updated accordingly.","Changes include replacing 'Company' with 'Surviving Corporation' in Sections 1.5 and 5.23, and updating the NRS statutory reference.","Overall terms of the Merger Agreement remain unchanged; the amendment is procedural for the previously announced acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98869,"accession_number":"0001193125-26-179085","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Ligand to acquire XOMA Royalty for $39.00/share cash plus contingent value rights","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Per-share consideration: $39.00 cash plus CVRs representing rights to 75% of net proceeds from Janssen litigation.","Support stockholders holding ~47% of shares agree to vote in favor; no financing condition for acquirer.","Transaction includes holding company reorganization and CVR spin; expected close by Jan 26, 2027.","Termination fee of $40M payable by XOMA under specified circumstances including superior proposal.","XOMA Board unanimously recommends approval; stockholder vote required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98868,"accession_number":"0001193125-26-181885","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K/A","filed_at":"2026-04-27T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"XOMA completes Generation Bio acquisition; estimates CVR value at $0.81/share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["XOMA paid $4.2913 per share cash plus one non-tradeable CVR for Generation Bio; ~70% of shares tendered.","CVR estimated at $0.81 per share, mainly from net cash above $29M; no value assigned to legacy assets.","Acquired ~$98M in Section 174 tax deductions and legacy LNP assets; no plans for preclinical development.","Moderna deal has up to ~$1.8B in milestones; next $7.5M milestone not expected within 12 months.","XOMA will use commercially reasonable efforts for 2 years to monetize legacy IP for CVR holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114578,"accession_number":"0001193125-26-112338","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"XOMA Royalty reports 2025 net income $31.7M vs loss $13.8M; royalties up 68% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year cash receipts $50.5M ($33.6M royalties, +68% YoY; $16.9M milestones); Q4 net income $6.1M vs loss $4.0M YoY.","Repurchased 648,048 shares for $16.0M; completed seven acquisitions adding 22 assets to portfolio.","Pipeline catalysts: volixibat Phase 2b data in PSC in Q2 2026; ersodetug Phase 3 data in tumor HI 2H 2026.","Seralutinib Phase 3 PAH missed primary endpoint; path forward discussions with FDA ongoing.","Litigation vs Janssen over TREMFYA IP continues; G&A includes $1.1M legal costs in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114577,"accession_number":"0001193125-26-084016","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"XOMA Royalty releases updated corporate presentation; financial data on pages 10-11 not extractable from exhibit snippet","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed March 2, 2026: updated corporate presentation made available as Exhibit 99.1.","Pages 10-11 of presentation incorporated by reference under Item 2.02 (financial results).","Exhibit text provided is truncated; no specific financial figures or forecasts are available.","Presentation intended for investor communication; no new leadership, M&A, or other material events stated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114576,"accession_number":"0001193125-26-042836","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"XOMA Royalty closes acquisition of Generation Bio for $4.2913/share plus CVR","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Completed tender offer; 4,722,533 shares (approx. 70%) tendered, all accepted.","Acquisition closed Feb 9, 2026; Generation Bio becomes wholly owned subsidiary.","CVRs entitle holders to 70-100% of Net Cash Excess and tiered shares of Legacy Assets and Moderna Collaboration proceeds.","Binney Lease arrangement allocates up to $30M for future lease payments; excess may flow to CVR holders.","Legacy Assets Transaction Proceeds range from 70% (Year 1-2) to 30% (Year 7-10) of Net Proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114573,"accession_number":"0001193125-26-033771","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K/A","filed_at":"2026-02-02T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"XOMA completes acquisition of LAVA legacy assets; details Pfizer, Janssen programs and CVR terms","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["XOMA completed acquisition of LAVA legacy assets (EGFRd2, JNJ-89853413, LAVA-1266) on Nov 20, 2025.","EGFRd2 (PF-8046052) outlicensed to Pfizer; potential milestones up to ~$650M; Phase 1 trial expected to complete 2029/2030.","JNJ-89853413 outlicensed to Janssen; potential milestones up to ~$195M; Phase 1 started Jan 2025, expected completion Aug 2028.","CVRs issued for 75% of net proceeds from future asset sales; XOMA valued CVRs at $0.00 due to early-stage uncertainty.","XOMA will use commercially reasonable efforts for 2 years to sell or license the legacy assets for CVR holders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114575,"accession_number":"0001193125-26-014142","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"XOMA Royalty names Jeffrey Trigilio CFO; Thomas Burns departs after ~19 years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas Burns stepped down as CFO effective Jan 12, 2026; separation agreement includes $16k/month consulting for 3 months.","Jeffrey Trigilio appointed CFO effective Jan 12; was CFO/COO at Obsidian Therapeutics and CFO at Cullinan Therapeutics.","Trigilio receives $515k base salary, 40% target bonus, initial grant of 30,000 performance units, and annual equity grant in 2026.","Severance for Trigilio: 0.75x base salary, pro-rated bonus, 9-month health benefits; doubled to 1.5x base+bonus on change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114574,"accession_number":"0001193125-26-009726","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"XOMA Royalty posts updated corporate presentation; no specific material changes disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed updated corporate presentation on Form 8-K dated January 12, 2026 (Exhibit 99.1).","Presentation excerpt provided only contains disclaimer and title; no new financial or strategic updates extractable.","Unable to assess specific portfolio, revenue, or milestone changes from truncated exhibit.","Routine FD disclosure; no material events, guidance, or transactions identified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130946,"accession_number":"0001193125-25-308794","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2025-12-05T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"XOMA Royalty completes acquisition of Mural Oncology for $2.035/share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Deal closed Dec 5, 2025; Mural shareholders received $2.035 cash per share.","Transaction approved by Mural shareholders on Oct 24, 2025; Irish High Court sanctioned Dec 3.","Mural shares ceased trading on Nasdaq effective Dec 5; will be delisted and deregistered.","XOMA Royalty acquired entire share capital of Mural via Irish scheme of arrangement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130945,"accession_number":"0001193125-25-290638","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"XOMA completes acquisition of LAVA Therapeutics for $1.04/share plus CVRs","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Subsequent Offering Period expired Nov 20, 2025; Post-Offer Reorganization effective same day.","All LAVA shareholders who did not tender receive cash ($1.04/share) and one CVR for future payments.","XOMA will file LAVA's financial statements and pro forma info in an amendment to this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130944,"accession_number":"0001193125-25-275971","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"XOMA Royalty Q3 net income $14.1M vs loss $17.2M; revenue $9.4M; cash receipts $43.9M YTD","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $14.1M in Q3 2025, compared to net loss of $17.2M in Q3 2024.","Revenue $9.4M (Q3) and $38.4M (9M), up from $7.2M and $19.8M in prior-year periods.","Cash receipts from partners: $14.3M in Q3; $43.9M in first nine months of 2025.","Recorded $17.9M gain on HilleVax acquisition and $1.8M gain on Turnstone in Q3.","Cash and equivalents $130.6M at Sept 30; repurchased ~108,510 shares for $2.4M YTD."],"consensus_eps_estimate":null,"consensus_eps_actual":1.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":38392000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130943,"accession_number":"0001193125-25-230466","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"XOMA enters ATM sales agreements for up to $125M in common stock and preferred depositary shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Up to $75M common stock ATM with Leerink Partners; 3% commission.","Up to $50M depositary shares (Series B preferred) ATM with H.C. Wainwright; 3% commission.","Proceeds intended for royalty acquisitions, working capital, and preferred dividends.","Offers registered under existing S-3 shelf (File No. 333-277794) effective June 2024.","Company is not obligated to sell any shares; may terminate agreements at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147522,"accession_number":"0001193125-25-220830","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"XOMA corrects typo in Series B preferred stock certificate of designation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Certificate of Correction filed Sept 23, 2025 for Series B Cumulative Perpetual Preferred Stock.","Typographical error in Section 8(a) corrected from \"1.253.13\" to \"1,253.13\".","Original Certificate of Designation filed May 29, 2025; no change to economic terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.02,"calibrated_materiality_score":0.02,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147521,"accession_number":"0001193125-25-213583","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2025-09-23T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"XOMA completes acquisition of HilleVax for $1.95 per share plus CVR","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["XOMA acquired HilleVax via tender offer and merger; offer price of $1.95 cash plus one CVR per share.","Approximately 77.48% of HilleVax shares were tendered (39,214,689 shares) and accepted.","Merger closed September 17, 2025; HilleVax is now a wholly owned subsidiary of XOMA.","CVR represents right to receive potential cash payments under CVR Agreement dated September 17, 2025.","Financial statements of HilleVax will be filed in an amendment to this Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147520,"accession_number":"0001193125-25-181840","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2025-08-15T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"XOMA completes acquisition of Turnstone Biologics for $0.34 cash plus CVR per share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["XOMA accepted 17,192,002 shares (~74% of outstanding) at $0.34 plus one CVR per share.","Merger completed under Section 251(h) of DGCL; no stockholder vote held.","Outstanding shares not tendered converted to $0.34 and one CVR; options cancelled for no consideration.","CVR Agreement dated Aug 11, 2025, with Broadridge as rights agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147519,"accession_number":"0001193125-25-179446","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"XOMA Royalty Q2 net income $9.2M; acquires Turnstone, HilleVax, LAVA; H1 cash receipts $29.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $9.2M (Q2 2025) vs $16.0M (Q2 2024); income & revenue $13.1M vs $11.1M.","H1 2025 cash receipts $29.6M ($16.0M royalties, $13.6M milestones); Q2 cash receipts $11.7M.","Completed Turnstone acquisition (Aug 11); HilleVax expected Sept; LAVA expected Q4 2025.","Deployed $20M for additional mezagitamab royalty; $5M milestone from Rezolute, $3M from Takeda.","Repurchased 107,500 shares in H1 for $2.4M; paid $2.7M in preferred stock dividends."],"consensus_eps_estimate":null,"consensus_eps_actual":0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":29041000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166174,"accession_number":"0001193125-25-132200","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["3.03","5.02","5.03","5.07","9.01"],"status":"ready","headline":"XOMA stockholders approve reincorporation to Nevada and increase in equity plan shares by 880,000","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reincorporation from Delaware to Nevada effective May 30, 2025; no change in business, management, or assets.","Amended 2010 Long Term Incentive Plan increases available shares by 880,000 and prohibits dividends on unvested awards.","All seven director nominees elected with votes ranging from 7.47M to 8.55M; Deloitte ratified as auditor.","Reincorporation proposal passed with 6.01M for and 2.55M against; plan amendment approved with 8.15M for.","Board authorized to unilaterally amend bylaws, approved with 8.41M for and 120,508 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166173,"accession_number":"0001193125-25-118322","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"XOMA Royalty Q1 net income $2.4M, total revenues $15.9M; adds Castle Creek royalty, sells Kinnate assets","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 total revenues $15.9M (vs $1.5M Q1 2024); net income $2.4M (vs net loss $8.6M).","Cash receipts $18.0M in Q1, including $13.4M royalties and $4.6M milestones; cash $95.0M at March 31.","Acquired Phase 3 royalty interest in Castle Creek's D-Fi (DEB) for $5M; sold all unpartnered Kinnate assets.","Milestone: $4.0M from Day One/Ipsen MAA filing for tovorafenib with EMA; $3.0M net from Takeda Phase 3 start (Q2).","Share repurchases: $0.5M for 25,828 shares; paid $1.4M in preferred dividends."],"consensus_eps_estimate":null,"consensus_eps_actual":0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":15912000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183662,"accession_number":"0001193125-25-055666","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"XOMA Royalty reports Q4/FY2024 revenue $28.5M, net loss $13.8M; portfolio doubled to 120+ assets","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $8.7M Q4, $28.5M FY2024 (vs $1.8M and $4.8M in 2023); net loss $4.0M Q4, $13.8M FY2024.","Cash and equivalents $106.4M at Dec 31, 2024; cash receipts totaled $46.3M in FY2024.","Doubled royalty portfolio to over 120 assets via five 2024 transactions: Twist ($15M), Daré ($22M), Talphera ($8M), Kinnate ($2.5879/sh + CVR), Pulmokine ($20M).","FDA approvals for Day One's OJEMDA and Zevra's MIPLYFFA; milestone payments received from both.","Non-cash credit losses $30.9M FY2024 (Agenus, Aronora, Talphera); management sees path to cash flow positive from royalties alone in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183661,"accession_number":"0001193125-25-024024","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K/A","filed_at":"2025-02-11T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"XOMA files Pulmokine financials for $20M cash acquisition closed Nov 26, 2024","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["XOMA acquired Pulmokine for $20M cash at closing; historical audited and unaudited financials filed.","Pulmokine 2023 revenue $10M (milestone) and net income $7.95M; cash $708K at year-end.","Pro forma condensed combined balance sheet and income statements filed as Exhibit 99.4.","Pulmokine is a biopharma developing inhaled PDGFR inhibitor for pulmonary arterial hypertension.","Exhibits include audited FY2023, unaudited 9M2024 financials, and independent auditor consent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200253,"accession_number":"0001193125-24-268497","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2024-12-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"XOMA Royalty acquires Pulmokine for $20M, adding seralutinib royalty/milestone interest","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Pulmokine for $20M cash at closing plus success-based consideration.","XOMA gets low- to mid-single-digit net royalty on seralutinib commercial sales.","XOMA retains up to $25M of future milestone payments tied to seralutinib.","Seralutinib (Phase 3 PAH) readout expected Q4 2025; developed by Gossamer/Chiesi.","This is XOMA's second whole-company acquisition in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200252,"accession_number":"0001193125-24-252618","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"XOMA Q3: Revenue $7.2M, net loss $17.2M ($14M impairment); Twist 50% interest acquired","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total income/revenue of $7.2M in Q3 2024 vs $0.8M in Q3 2023; cash receipts $9.9M.","Net loss of $17.2M vs $5.5M loss, driven by $14M non-cash impairment on Agenus royalty purchase agreement.","Acquired 50% economic interest in Twist Bioscience's 60+ partnered early-stage programs for $15M.","Cash and cash equivalents of $146.8M at Sept 30, 2024, down from $159.6M at Dec 31, 2023.","Zevra's MIPLYFFA (arimoclomol) received FDA approval for Niemann-Pick disease type C, adding commercial royalty."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":19773000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200251,"accession_number":"0001193125-24-240757","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"XOMA Royalty acquires 50% of Twist Bioscience's royalty/milestone economics for $15M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Acquired 50% economic interest in milestones/royalties from Twist's 60+ early-stage programs across 30 partners for $15M upfront.","XOMA's portfolio now exceeds 100 assets, spanning commercial to pre-clinical programs.","Twist's Biopharma Solutions business unit yields future payments under biopharma services agreements.","Chief Investment Officer Brad Sitko cites potential for superior risk-adjusted returns.","Gibson, Dunn & Crutcher served as XOMA's legal advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216269,"accession_number":"0001193125-24-223242","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves Zevra's MIPLYFFA for NPC; XOMA holds royalty on sales up to $52.6M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA approved MIPLYFFA (arimoclomol) for Niemann-Pick disease type C (NPC) on Sept 20, 2024.","XOMA is entitled to a mid-single digit royalty on commercial sales of MIPLYFFA.","XOMA may receive up to $52.6 million (net) in milestone payments from Zevra.","MIPLYFFA is the sixth commercial asset in XOMA's royalty and milestone portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216268,"accession_number":"0001193125-24-199416","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"XOMA Royalty Q2 net income $16.0M; receives $22.6M cash; acquires Kinnate and Daré rights; posts $9.0M impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $16.0M vs net loss $5.4M in Q2 2023; total income/revenue $11.1M; cash receipts $22.6M.","Completed acquisition of Kinnate Pharmaceuticals, adding >$9.5M cash and potential royalty streams; acquired Daré's XACIATO, Ovaprene, Sildenafil Cream rights.","Recorded $9.0M non-cash impairment on Aronora programs; $19.3M gain on Kinnate acquisition, partially offset by $8.1M derivative charge.","Zevra's arimoclomol received favorable advisory committee vote; FDA PDUFA date Sept 21, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":12576000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216267,"accession_number":"0001193125-24-176579","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2024-07-09T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"XOMA Corporation changing name to XOMA Royalty Corporation on July 10, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change effective 12:01 a.m. ET on July 10, 2024; ticker 'XOMA' and CUSIP unchanged.","No stockholder vote required; amendment filed under Delaware General Corporation Law Section 242.","Existing stock certificates remain valid; voting and transfer rights unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235828,"accession_number":"0001193125-24-160743","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K/A","filed_at":"2024-06-13T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"XOMA closes Kinnate acquisition for $122.7M cash; Q1 2024 pro forma net loss $21.7M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cash consideration of $2.5879 per share + one CVR; aggregate cash $122.7M financed from cash on hand.","Kinnate Q1 2024 net loss $13.1M, cash $151.3M at March 31, 2024.","Pro forma combined net loss for Q1 2024 $21.7M; for FY 2023 $136.9M.","Kinnate restructuring costs of $2.3M in Q1 2024; workforce reductions implemented.","Includes historical audited financials of Kinnate as of Dec 31, 2023 and 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235834,"accession_number":"0001193125-24-150435","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"XOMA to receive $8.1M from Viracta after Day One sells PRV for $108M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Day One Biopharmaceuticals sold a priority review voucher for $108M after FDA approval of OJEMDA.","XOMA is entitled to $8.1M from Viracta under a March 2021 agreement covering tovorafenib milestones.","The PRV sale proceeds trigger event-based economics payable to XOMA.","Funds represent a portion of the PRV proceeds passed through from Day One to Viracta."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235833,"accession_number":"0001193125-24-140003","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"XOMA shareholders elect all seven director nominees and ratify Deloitte as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected with >99% votes for (excluding broker non-votes).","Ratification of Deloitte & Touche as auditor passed with 7,872,497 votes for (99.3%).","Broker non-votes on director election totaled 899,715 shares.","Total shares outstanding: 11,635,015; meeting held May 15, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235832,"accession_number":"0001193125-24-134777","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"XOMA Q1 net loss $8.6M; FDA approves OJEMDA triggering $9M milestone","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $1.5M (vs $0.4M YoY) on $1M AVEO milestone; net loss $8.6M (vs $9.8M YoY).","FDA approved Day One's OJEMDA; XOMA earned $9M milestone and will receive mid-single digit royalties.","Acquired Kinnate Pharmaceuticals for $2.5879/share + CVR; adds at least $9.5M non-dilutive capital.","Expanded royalty portfolio: economic interests in DSUVIA, XACIATO, Ovaprene (Ph3), and Sildenafil Cream.","Launched first $50M stock buyback; cash $142.4M at March 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":1490000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235831,"accession_number":"0001193125-24-123689","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"XOMA pays $22M upfront for royalty interests in three women's health assets from Daré Bioscience","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["XOMA paid $22M cash to Daré for royalties on XACIATO, Ovaprene, and Sildenafil Cream.","XOMA receives low-to-high single-digit royalties on XACIATO net sales; Organon began marketing in Q4 2023.","Synthetic royalties: low single-digit on Ovaprene (Phase 3) and Sildenafil Cream (Phase 3-ready), decreasing after return threshold.","XOMA also acquires a portion of a milestone payment from Bayer related to Ovaprene.","XOMA will make upside-sharing milestone payments to Daré upon achieving a pre-specified return threshold."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235830,"accession_number":"0001193125-24-111613","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"XOMA earns $9M milestone on FDA approval of Day One's OJEMDA for pediatric low-grade glioma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["XOMA earned $9M milestone from FDA accelerated approval of Day One's OJEMDA (tovorafenib) for relapsed/refractory BRAF-altered pLGG.","XOMA is entitled to a mid-single digit royalty on global OJEMDA sales; it is the first FDA-approved type II RAF inhibitor for this indication.","XOMA acquired rights in March 2021 from Viracta for $13.5M upfront, including $54M in potential milestones and royalties.","CEO Owen Hughes called the milestone a watershed event for children with BRAF-altered low-grade glioma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235829,"accession_number":"0001193125-24-085545","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"XOMA completes acquisition of Kinnate Biopharma for $2.5879 per share plus CVRs","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["XOMA purchased ~81% of Kinnate shares via tender offer at $2.5879/share plus one CVR per share.","Merger closed under DGCL Section 251(h); remaining shares converted to same consideration.","CVRs entitle holders to potential payments from future disposition of Kinnate's products within one year, up to five years.","Total of 38,258,681 shares tendered; all conditions satisfied for merger.","XOMA expects to realize value from Kinnate's pipeline; CVR agreement filed as exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253587,"accession_number":"0001193125-24-062926","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"XOMA reports Q4 2023 net loss $20.1M, revenue $1.8M; cash $159.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2023 net loss $40.8M vs $17.1M in 2022; revenue $4.8M vs $6.0M.","Closed $130M royalty-backed loan from Blue Owl for VABYSMO; cash and equivalents $159.6M.","Acquired economic interest in DSUVIA for $8M in Jan 2024; announced $50M stock repurchase program.","Owen Hughes appointed CEO, Jack Wyszomierski named Chairman effective Jan 7, 2024.","Received $15.5M in cash payments from royalties and milestones in 2023; $7.3M from VABYSMO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253586,"accession_number":"0001193125-24-038129","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2024-02-16T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"XOMA to acquire Kinnate Biopharma for up to $2.5879 per share plus CVR","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cash consideration of $2.3352 base plus up to $0.2527 additional per share; plus CVR for 85% or 100% of program sale proceeds.","Kinnate must have at least $120M net cash at closing; expected close in April 2024.","XOMA expects to add ~$9.5M cash to balance sheet and acquire early-stage oncology programs.","Support agreements covering ~46% of Kinnate shares signed; Kinnate board unanimously approved.","Tender offer to commence by March 4, 2024; financing condition waived."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253585,"accession_number":"0001193125-24-006629","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2024-01-11T23:59:59+00:00","items":["5.02","7.01"],"status":"ready","headline":"XOMA appoints Owen Hughes as permanent CEO, boosts salary to $575K; chairman changes","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Owen Hughes, previously interim CEO, appointed CEO and director effective Jan 7, 2024; base salary raised to $575,000.","Target annual cash bonus set at 60% of base salary; 275,000 performance share units granted vesting on stock price milestones.","Jack Wyszomierski, former Lead Independent Director, appointed Chairman of the Board; Hughes steps down as Executive Chairman.","Amended employment agreement includes severance: 1x salary (non-CIC) or 2x salary plus bonus acceleration (CIC-related)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253584,"accession_number":"0001193125-24-000224","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"XOMA announces first stock repurchase program of up to $50M through January 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized repurchase of up to $50M of common stock through January 2027.","This is XOMA's first repurchase program; part of balanced capital allocation strategy.","Management has discretion on timing, structure, and method (open market, private negotiations).","Program may be suspended, modified, or terminated at any time by the Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271046,"accession_number":"0001193125-23-298155","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2023-12-19T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"XOMA secures up to $140M non-dilutive royalty-backed loan from Blue Owl at 9.875%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["XOMA draws $130M initial term loan; can draw additional $10M if VABYSMO royalties exceed threshold by March 2026.","Semi-annual interest at 9.875% fixed; 15-year maturity with optional prepayment; loan is non-recourse to XOMA assets.","Issued Blue Owl warrants for 120,000 shares in three tranches at $35, $42.50, and $50 per share (122%-217% premium).","Proceeds to fund stock repurchases and additional royalty/milestone acquisitions, per CIO Brad Sitko.","Loan backed by VABYSMO (faricimab) royalties; XOMA acquired these royalties for $14M in 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271045,"accession_number":"0001193125-23-271925","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"XOMA reports Q3 net loss of $5.5M, highlights NDA filings and $5M milestone from Day One","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenues $0.8M vs $0.5M YoY; net loss $5.5M vs $4.2M YoY.","G&A expenses $6.4M including $2.7M non-cash stock comp; net cash used in ops $2.1M.","Received $6.6M in royalty & milestone payments; ended Q3 with $33.5M cash.","Subsequent: earned $5M milestone from Day One on FDA acceptance of tovorafenib NDA; PDUFA April 30, 2024.","Organon terminated license for ebopiprant; XOMA to seek out-licensing."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":2925000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271044,"accession_number":"0001193125-23-266722","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"XOMA eligible for $5M milestone from FDA acceptance of Day One's NDA for tovorafenib in pediatric glioma","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA accepted Day One Biopharmaceuticals' NDA for tovorafenib as monotherapy for relapsed/progressive pediatric low-grade glioma.","XOMA now eligible for a $5 million milestone payment from Day One under the tovorafenib royalty purchase agreement.","XOMA originally acquired up to $54M in milestones and mid-single digit royalties on tovorafenib from Viracta in March 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":271043,"accession_number":"0001193125-23-265233","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2023-10-27T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Organon terminates ebopiprant license agreement with XOMA; XOMA to seek new partner","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Organon notified XOMA of intent to terminate License Agreement for ebopiprant; effective Jan 21, 2024.","Termination is for convenience; no milestone payments for achievements after notice; no early termination penalties.","XOMA to seek to out-license ebopiprant for further development.","License agreement originally between Organon and ObsEva (July 2021), assumed by XOMA in Nov 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287929,"accession_number":"0001193125-23-232464","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2023-09-11T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"XOMA receives $4.9M commercial payment from Genentech for VABYSMO H1 2023 sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received $4.9 million from Genentech (Roche) for VABYSMO net sales in first six months of 2023.","Payment reflects 0.5% royalty stream on VABYSMO sales in certain regions for ten years from first commercial sale.","XOMA acquired this royalty interest through an October 2021 purchase agreement with Affitech Research AS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287928,"accession_number":"0001193125-23-221604","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2023-08-25T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Novartis discontinues development of XOMA-licensed NIS793 anti-TGFß antibody","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Aug 25, 2023, Novartis notified XOMA it will stop development of NIS793 (anti-TGFß monoclonal antibody).","Novartis will cease enrolling patients in remaining active TGFß clinical studies and collect final data.","XOMA licensed NIS793 to Novartis in September 2015; no milestones or royalties mentioned in the filing.","NIS793 is investigational; efficacy/safety not established and no guarantee of commercial availability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287927,"accession_number":"0001193125-23-205589","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"XOMA Q2 net loss $5.4M; revenue $1.7M, cash $31.4M; two royalty deals in H1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $1.7M (Q2 2022: $1.0M), driven by $1.1M milestone from Janssen license.","Net loss $5.4M vs $4.7M in Q2 2022; includes $1.6M non-cash impairment on Bioasis royalty.","Cash and equivalents $31.4M at June 30, 2023, down from $57.8M at Dec 31, 2022.","Net cash used in operations $7.2M, including $4.1M one-time arbitration settlement cost.","Expects lower milestone receipts in 2023 due to partner delays; cash sufficient for multiple years."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":2095000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287926,"accession_number":"0001193125-23-188532","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2023-07-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Novartis discontinues Phase 3 trial of XOMA-licensed NIS793 in pancreatic cancer; continues in colorectal cancer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Novartis stopped Phase 3 trial (NCT04935359) of NIS793 in first-line metastatic PDAC based on benefit-risk assessment.","Trial compared NIS793 plus gem/nab-paclitaxel vs placebo plus gem/nab-paclitaxel; no efficacy or safety established.","Novartis will continue investigating NIS793 in other indications, including a Phase 2 study in colorectal cancer.","XOMA licensed NIS793 to Novartis in September 2015 under a license agreement previously filed with the SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308278,"accession_number":"0001193125-23-171784","cik":791908,"company_name":"XOMA Royalty Corp","ticker":"XOMA","form_type":"8-K","filed_at":"2023-06-22T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"XOMA acquires LadRx royalty/milestone rights for arimoclomol and aldoxorubicin for $5M upfront","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 100% of LadRx's royalty and milestone rights for arimoclomol (NPC) and aldoxorubicin (ImmunityBio).","Paid $5M upfront; additional milestone payments of up to $6M may be required.","Arimoclomol rights: $52.6M net milestones and mid-single-digit royalty from Zevra.","Aldoxorubicin rights: mid-single-digit to mid-teens royalties and up to $343M milestones from ImmunityBio.","Agreements include customary covenants, representations, and indemnification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":520950000.00000006,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-06-22T23:59:59+00:00|308278"}